Cargando…

The heterogeneous landscape of ALK negative ALCL

Anaplastic Large Cell Lymphoma (ALCL) is a clinical and biological heterogeneous disease including systemic ALK positive and ALK negative entities. Whereas ALK positive ALCLs are molecularly characterized and readily diagnosed, specific immunophenotypic or genetic features to define ALK negative ALC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mereu, Elisabetta, Pellegrino, Elisa, Scarfò, Irene, Inghirami, Giorgio, Piva, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392347/ https://www.ncbi.nlm.nih.gov/pubmed/28061468 http://dx.doi.org/10.18632/oncotarget.14503

Ejemplares similares

P1235: INVESTIGATION OF THE CO-MUTATIONAL LANDSCAPE OF ALK-POSITIVE ALCL
por: Villa, Matteo, et al.
Publicado: (2023)

The DNA-helicase HELLS drives ALK(−) ALCL proliferation by the transcriptional control of a cytokinesis-related program
por: Tameni, Annalisa, et al.
Publicado: (2021)

ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma
por: Tabbó, Fabrizio, et al.
Publicado: (2012)

ALK expression favorably impacts the prognosis of NRAS-mutated metastatic melanomas
por: Osella-Abate, Simona, et al.
Publicado: (2018)

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL
por: Hare, Lucy, et al.
Publicado: (2021)

ALK+ ALCL in the setting of adalimumab‐related hidradenitis suppurativa
por: Craig, Alexander, et al.
Publicado: (2023)

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
por: Paradzik, Tina, et al.
Publicado: (2021)

Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research
por: Deva, Anand K., et al.
Publicado: (2020)

The Dual Role of Autophagy in Crizotinib-Treated ALK(+) ALCL: From the Lymphoma Cells Drug Resistance to Their Demise
por: Espinos, Estelle, et al.
Publicado: (2021)

PB2372: PP2A INHIBITOR LB100 ENHANCES THE SENSITIVITY OF NPM-ALK+ALCL TO CRIZOTINIB AND REVERSES THE RESISTANCE OF ALCL TO CRIZOTINIB
por: Shi, Wenyu
Publicado: (2023)

ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment
por: Chioureas, Dimitrios, et al.
Publicado: (2022)

From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)
por: Werner, Michael T., et al.
Publicado: (2017)

Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs
por: Pearson, Joel D, et al.
Publicado: (2014)

STAT3 Mutation Is Associated with STAT3 Activation in CD30(+) ALK(−) ALCL
por: Andersson, Emma I., et al.
Publicado: (2020)

Erratum to: ‘Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs’
por: Pearson, Jodel D., et al.
Publicado: (2016)

Revealing the true face behind the mask of ALK-positive anaplastic large cell lymphoma (ALCL)
por: Eisfeld, Hannah, et al.
Publicado: (2020)

Primary Cutaneous CD30+/ALK- ALCL with Transition into sALCL: Favourable Response after Systemic Administration with Brentuximab Vedotin! Unique Presentation in a Bulgarian Patient!
por: Popova, Tanya Naskova, et al.
Publicado: (2018)

De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells
por: Babin, Loélia, et al.
Publicado: (2022)

Primary Anaplastic Lymphoma Kinase (ALK)-Negative Anaplastic Large Cell Lymphoma (ALCL) Presenting as Perforation Peritonitis: A Case Report and Management Principles
por: Sanker, Vivek, et al.
Publicado: (2022)

AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL
por: Wu, Zuoqiao, et al.
Publicado: (2021)

Abstract 11: A Novel Tissue Engineered Three-Dimensional Biomimetic Platform for In Vitro Study of BIA-ALCL
por: Wright, Matthew A., et al.
Publicado: (2019)

4485 Silicone Implant Shells Increase the Rate of Proliferation of Patient-Derived BIA-ALCL Cells but Not Primary T Cells in an Engineered Biomimetic Breast Platform
por: Premaratne, Ishani, et al.
Publicado: (2020)

Next-Generation Sequencing Identifies Deregulation of MicroRNAs Involved in Both Innate and Adaptive Immune Response in ALK+ ALCL
por: Steinhilber, Julia, et al.
Publicado: (2015)

Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK(+) ALCL: results of COG trial ANHL12P1
por: Lowe, Eric J., et al.
Publicado: (2021)

PB2125: LYMPHOMATOID PAPULOSIS-LIKE (LYP-LIKE) AFTER BRENTUXIMAB VEDOTIN-CHP (BV-CHP) TREATMENT FOR ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)
por: Lopez Pereira, P., et al.
Publicado: (2022)

Phosphorylated STAT3 as a potential diagnostic and predictive biomarker in ALK(-) ALCL vs. CD30(high) PTCL, NOS
por: Xiang, Chenxi, et al.
Publicado: (2023)

BIA-ALCL-Horizon Scanning
por: Mallucci, Patrick, et al.
Publicado: (2022)

Identification of C/EBPβ Target Genes in ALK+ Anaplastic Large Cell Lymphoma (ALCL) by Gene Expression Profiling and Chromatin Immunoprecipitation
por: Bonzheim, Irina, et al.
Publicado: (2013)

Anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) of breast in a patient without a breast implant
por: Sathyanarayanan, Vishwanath, et al.
Publicado: (2014)

BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL
por: Garland, Gavin D., et al.
Publicado: (2021)

CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL
por: Montes-Mojarro, Ivonne-Aidee, et al.
Publicado: (2022)

The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL)
por: Montes-Mojarro, Ivonne A., et al.
Publicado: (2018)

Abstract 125: Silicone Implant Shells Increase The Rate Of Proliferation Of Patient-derived BIA-ALCL Cells But Not Primary T Cells In An Engineered Biomimetic Patient-derived Breast Tissue
por: Premaratne, Ishani D., et al.
Publicado: (2020)

EBP2, a novel NPM‐ALK‐interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53
por: Uchihara, Yuki, et al.
Publicado: (2020)

Silicone Implant Shells Increase the Rate of Proliferation of Alk- but Not Alk+ Lymphoma Cells in an Engineered Biomimetic Breast Microenvironment
por: Premaratne, Ishani D., et al.
Publicado: (2020)

A Multidimensional Investigation of BIA-ALCL and Systemic ALCL Proliferation Rates in Response to Silicone Implant Shells and the Breast Microenvironment
por: Ann Askinas, Carly, et al.
Publicado: (2022)

Fundamental features of AlCl(4)(−)-/AlCl(4)-graphite intercalation compounds of aluminum-ion-based battery cathodes
por: Li, Wei-Bang, et al.
Publicado: (2022)

Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL)
por: Lee, Jun-Ho
Publicado: (2021)

ALK-Negative Anaplastic Large Cell Lymphoma: Current Concepts and Molecular Pathogenesis of a Heterogeneous Group of Large T-Cell Lymphomas
por: Pina-Oviedo, Sergio, et al.
Publicado: (2021)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
por: Gristina, Valerio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_27c7n0diukp5g1v756572d9hkk